The stock of Elevation Oncology Inc (ELEV) has gone down by -3.82% for the week, with a -1.18% drop in the past month and a 4.47% rise in the past quarter. The volatility ratio for the week is 12.28%, and the volatility levels for the past 30 days are 11.24% for ELEV. The simple moving average for the last 20 days is -3.95% for ELEV’s stock, with a simple moving average of -71.55% for the last 200 days.
Is It Worth Investing in Elevation Oncology Inc (NASDAQ: ELEV) Right Now?
ELEV has 36-month beta value of 1.26. Analysts have mixed views on the stock, with 4 analysts rating it as a “buy,” 3 as “overweight,” 0 as “hold,” and 0 as “sell.”
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
The public float for ELEV is 52.02M, and currently, short sellers hold a 11.83% ratio of that float. The average trading volume of ELEV on December 26, 2024 was 786.21K shares.
ELEV) stock’s latest price update
The stock price of Elevation Oncology Inc (NASDAQ: ELEV) has jumped by 6.60 compared to previous close of 0.56. Despite this, the company has seen a fall of -3.82% in its stock price over the last five trading days. prnewswire.com reported 2024-12-12 that — EO-1022 is comprised of seribantumab, an anti-HER3 monoclonal antibody, and an MMAE payload – — Following recently signed global license agreement with Synaffix, EO-1022 leverages the company’s GlycoConnect® and HydraSpace® ADC technologies for glycan site-specific conjugation and SYNstatin E™ linker-payload — – Elevation Oncology expects to present EO-1022 preclinical data in 1H 2025 and to file an IND application in 2026 – BOSTON, Dec. 12, 2024 /PRNewswire/ — Elevation Oncology, Inc. (Nasdaq: ELEV), an innovative oncology company focused on the discovery and development of selective cancer therapies to treat patients across a range of solid tumors with significant unmet medical needs, today announced the nomination of EO-1022 as its HER3 ADC development candidate. EO-1022 is currently progressing through preclinical development, and Elevation Oncology expects to file an investigational new drug (IND) application in 2026.
Analysts’ Opinion of ELEV
Many brokerage firms have already submitted their reports for ELEV stocks, with Piper Sandler repeating the rating for ELEV by listing it as a “Overweight.” The predicted price for ELEV in the upcoming period, according to Piper Sandler is $10 based on the research report published on May 31, 2024 of the current year 2024.
Stephens, on the other hand, stated in their research note that they expect to see ELEV reach a price target of $8. The rating they have provided for ELEV stocks is “Overweight” according to the report published on May 14th, 2024.
JMP Securities gave a rating of “Mkt Outperform” to ELEV, setting the target price at $7 in the report published on March 01st of the current year.
ELEV Trading at -0.62% from the 50-Day Moving Average
After a stumble in the market that brought ELEV to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -89.69% of loss for the given period.
Volatility was left at 11.24%, however, over the last 30 days, the volatility rate increased by 12.28%, as shares sank -3.95% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading +15.84% upper at present.
During the last 5 trading sessions, ELEV fell by -4.57%, which changed the moving average for the period of 200-days by -85.26% in comparison to the 20-day moving average, which settled at $0.6261. In addition, Elevation Oncology Inc saw 11.94% in overturn over a single year, with a tendency to cut further gains.
Stock Fundamentals for ELEV
Current profitability levels for the company are sitting at:
- -724.26 for the present operating margin
- 0.5 for the gross margin
The net margin for Elevation Oncology Inc stands at -723.24. The total capital return value is set at -0.42. Equity return is now at value -63.67, with -40.67 for asset returns.
Based on Elevation Oncology Inc (ELEV), the company’s capital structure generated 0.31 points at debt to capital in total, while cash flow to debt ratio is standing at -1.24. The debt to equity ratio resting at 0.45. The interest coverage ratio of the stock is -8.76.
Currently, EBITDA for the company is -41.47 million with net debt to EBITDA at 0.41. When we switch over and look at the enterprise to sales, we see a ratio of 312.7. The liquidity ratio also appears to be rather interesting for investors as it stands at 17.77.
Conclusion
To put it simply, Elevation Oncology Inc (ELEV) has had a mixed performance in recent times. Analysts have a bullish opinion on the stock, with some rating it as a “buy” and others as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
